Fiocruz obtained a patent from the US Patent Office for a malaria treatment method using the DAQ compound. The compound showed efficacy against resistant strains of the Plasmodium falciparum parasite, responsible for the most severe forms of the disease.
Malaria is caused by Plasmodium parasites, with P. falciparum responsible for the most severe forms of the disease. The parasite has developed resistance to traditional medications, creating the need for new therapeutic alternatives to prevent a shortage of effective treatments in the future.
Fiocruz obtained a patent from the United States Patent and Trademark Office (USPTO) for a treatment method using the DAQ compound
The DAQ compound demonstrated capacity against resistant strains of Plasmodium falciparum
DAQ's antimalarial activity was described in the 1960s, but the Fiocruz group resumed studies
The patent was granted in March 2026 and is valid until September 5, 2041
Development of DAQ as a drug still depends on toxicity testing and other stages
Covered by only some sources, or where the accounts diverge.
No gaps or divergences found — sources converge.
No gaps declared — all sources converge on the material facts.